In the present study, several oncogenic RTKs, including EGFR, c-Met, HER3, and c-Kit (Figure 2 and Figure 3), were found to be co-activated in HCC in the patient-derived hepatoma cells, HCC413. This evidence concerns the gene KIT and hepatocellular carcinoma.